When naming medicinal products the MHRA will ensure:No confusion with the name of another medicinal product

  • No misleading therapeutic and/or pharmaceutical connotations
  • No misleading impressions as to the composition of the product
  • No phonetics/difficulties in its pronunciation are considered
  • Numbers are avoided, to reduce confusion with its strength
  • It doesn’t convey a promotional message regarding its efficacy
  • It is not offensive or has an inappropriate connotation
  • It is different from the name of the active substance of the product
  • Its not an acronym, or contain code numbers/punctuation marks
  • Labelling/pack design in the context of its safe use is considered
  • The international non-proprietary name (INN) of a medicinal product is not used. Article 1(20) of Directive 2001/83/EC (ref2), ” an invented name shall not be liable to confusion with the common name..”

We hope this article was of interest, but please be aware it does not constitute legal advice.

Please contact wendy@lslawservices.com with any queries or visit here.